share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-10% Owner Cormorant Asset Management, LP

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-10% Owner Cormorant Asset Management, LP

EyePoint Pharmaceuticals | 4:持股变动声明-股东 Cormorant Asset Management, LP
美股SEC公告 ·  05/08 17:03

Moomoo AI 已提取核心信息

Cormorant Asset Management, LP has completed the purchase of shares in EyePoint Pharmaceuticals, Inc. (EYPT) on May 6, 2024. The transactions were executed in the open market with a total of 850,000 shares acquired. The first transaction involved the purchase of 642,847 shares at a price of $11.70 per share, while the second transaction saw 207,153 shares bought at $12.36 each. Following these transactions, Cormorant Asset Management's indirect beneficial ownership in EyePoint Pharmaceuticals totals 8,325,000 shares. The nature of the indirect beneficial ownership is detailed in a footnote not provided in this summary.
Cormorant Asset Management, LP has completed the purchase of shares in EyePoint Pharmaceuticals, Inc. (EYPT) on May 6, 2024. The transactions were executed in the open market with a total of 850,000 shares acquired. The first transaction involved the purchase of 642,847 shares at a price of $11.70 per share, while the second transaction saw 207,153 shares bought at $12.36 each. Following these transactions, Cormorant Asset Management's indirect beneficial ownership in EyePoint Pharmaceuticals totals 8,325,000 shares. The nature of the indirect beneficial ownership is detailed in a footnote not provided in this summary.
Cormorant Asset Management, LP已于2024年5月6日完成了对EyePoint Pharmicals, Inc.(埃及)股份的收购。这些交易在公开市场上执行,共收购了85万股股票。第一笔交易涉及以每股11.70美元的价格购买642,847股股票,而第二笔交易以每股12.36美元的价格购买了207,153股股票。这些交易之后,Cormorant资产管理公司对EyePoint Pharmicals的间接实益所有权共计8,325,000股。本摘要中未提供的脚注详细说明了间接受益所有权的性质。
Cormorant Asset Management, LP已于2024年5月6日完成了对EyePoint Pharmicals, Inc.(埃及)股份的收购。这些交易在公开市场上执行,共收购了85万股股票。第一笔交易涉及以每股11.70美元的价格购买642,847股股票,而第二笔交易以每股12.36美元的价格购买了207,153股股票。这些交易之后,Cormorant资产管理公司对EyePoint Pharmicals的间接实益所有权共计8,325,000股。本摘要中未提供的脚注详细说明了间接受益所有权的性质。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息